NEW YORK (GenomeWeb) – Biocept said today that it has signed a provider agreement with Alliance Global to market and distribute its Target Selector liquid biopsy tests in the United Arab Emirates, as well as select countries in the Middle East, North and Sub-Saharan Africa, and Southeast Asia region.
Under the agreement, Biocept will perform all diagnostic testing services in its San Diego CLIA-certified laboratory. Alliance Global will be responsible for sales, marketing, distribution, and reimbursement. Additional terms of the agreement were not disclosed.
Biocept offers a menu of blood-based biomarker testing including targets associated with both genomic and immunotherapies.
According to Nassim-Marie Hambouz, group director of commercial operations at Alliance Global, a major focus of its distribution efforts will be to market Biocept's testing services to global biopharmaceutical companies interested in qualifying patients for their targeted therapies.
Biocept CEO Michael Nall said in a statement that the company now has eight international agreements for the distribution of Target Selector tests across 17 countries outside the US.